[The use of the determination of the immune competence of patients with malignant tumors of the maxillofacial area for making a diagnosis and prognosis].
The value of evidence of pretherapeutic investigations with the leucocyte adherence inhibition assay (LAI) for 5-year prognosis we examined in 42 patients with malignant tumors of the maxillo-facial region. We found a tendency of higher frequency of recurrence in patients with preoperative positive LAI, but this was not statistically significant. In 19 patients we accomplished follow-up studies until 20 months after operation. Here we found no false-positive LAI, so that a positive LAI indicated always a tumor recurrence (33% of patients with recurrence), but two thirds of patients with recurrence reacted negative. In conclusion the LAI is of too small sensitivity and of too high expense.
Teuber
S
S
Köhler
M
M
D003937:Diagnosis, Differential; D005153:Facial Neoplasms / Q000175:diagnosis* / Q000628:therapy; D005500:Follow-Up Studies; D006801:Humans; D007121:Immunocompetence / Q000276:immunology*; D007573:Jaw Neoplasms / Q000175:diagnosis* / Q000628:therapy; D007957:Leukocyte Adherence Inhibition Test; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D011184:Postoperative Period; D011379:Prognosis; D013997:Time Factors
Zum Nutzen der Bestimmung der Immunkompetenz von Patienten mit malignen Tumoren des Kiefer-Gesichts-Bereiches für Diagnosestellung und Prognose.